Rtw Investments 13F: Cuts Zai Lab (ZLAB) Stake by $6.6M

RTW Investments has decreased its stake in ZLAB by 385,000 shares, according to its latest filing with the SEC. The filing, which reflects holdings as of the reporting period, shows that RTW now holds about 6.57 million shares valued at $112.2 million. This represents a 5.5% reduction from its previous position.

What Changed in RTW Investments' ZLAB Position

RTW Investments trimmed its position in ZLAB from 6.96 million shares to 6.57 million shares. The reduction of 385,000 shares marks a 5.5% decrease in its holdings. Despite this cut, the fund's stake in ZLAB remains substantial, with the shares valued at approximately $112.2 million.

Other Institutional Activity in ZLAB

Several other institutional investors also adjusted their positions in ZLAB. RA Capital Management added significantly, now holding 5.71 million shares valued at about $107.4 million. Frazier Life Sciences Management maintained its position with 1.9 million shares worth $35.8 million. Citadel Advisors slightly increased its holdings by 786 shares, totaling 1.69 million shares valued at $31.8 million. Meanwhile, Bamco Inc. boosted its stake by 240,313 shares to 1.66 million shares, valued at $31.2 million, and Adar1 Capital Management increased its holdings by 178,847 shares to 1.43 million shares, valued at $26.8 million.

Zai Lab Limited Stock Down 33.6%

Shares of ZLAB recently traded near $17.07. The stock has experienced fluctuations in institutional interest, as evidenced by recent filings. Investors are watching to see how these changes will affect the company's performance in the market.

Insider Buying and Selling at Zai Lab Limited

There has been notable insider activity at ZLAB. On May 11, Operating Partner Wang Yizhe purchased 136,819 shares and an additional 59,288 shares on the same day. Chairperson and CEO Du Ying had mixed transactions, selling 87,843 shares on May 27 and 19,857 shares on May 26, while buying 261,092 shares at $1.74 on May 19 and selling 117,435 shares at $18.75 on the same day.

Analysts Set New Price Targets

Analysts remain optimistic about ZLAB's prospects. On May 8, Citigroup maintained its buy rating with a price target of $44. JP Morgan also kept its buy rating, setting a $32 target on March 18. Cantor Fitzgerald echoed this sentiment, maintaining a buy rating with a $37 target on February 27. UBS initiated coverage with a buy rating and a $35 target on January 7.

Bottom Line

RTW Investments' recent reduction in ZLAB shares is a part of the dynamic landscape of institutional investments. These filings provide a snapshot of holdings as of the reporting period and may not reflect current positions. Investors keep a close eye on these changes and analyst ratings to gauge market sentiment and potential future movements.